Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17500452 | 0.85 | BRD4 (0.35) | VDRBRD4SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL26698693 | 0.82 | VDR (0.35) | F10CES2CES1VDRBRD4 | |
| SCHEMBL712214 | 0.81 | FFAR3 (0.36) | VDR | |
| SCHEMBL29635887 | 0.79 | F10 (0.40) | F10CES2CES1BRD4SMN1; SMN2 | |
| SCHEMBL22516380 | 0.79 | F10 (0.40) | F10CES2CES1BRD4SMN1; SMN2 | |
| SCHEMBL22516378 | 0.79 | F10 (0.40) | F10CES2CES1BRD4SMN1; SMN2 | |
| SCHEMBL14154941 | 0.79 | F10 (0.40) | F10CES2CES1BRD4SMN1; SMN2 | |
| SCHEMBL11302329 | 0.76 | CYP1A2 (0.44) | F10CES2CES1BRD4SMN1; SMN2 | |
| SCHEMBL16167662 | 0.75 | NPSR1 (0.36) | VDR | |
| SCHEMBL1543229 | 0.75 | F10 (0.36) | F10CES2CES1BRD4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487483-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-11-08 | — | — | US | disclosed |
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | F10 117/4885CES2 4015/4885CES1 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.